ASX Announcement Independent Data Monitoring Committee to Review Phase 3 Clinical Trial Data of Recce’s Topical Gel for Diabetic Foot Ulcer Infections Highlights: • Review of the blinded data indicates strong efficacy across the study population ® • RECCE 327 Gel (R327G) continues to...
Independent Review of Indonesian Phase 3 R327G Trial Data
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Patient recruitment and dosing will continue while the DMC conducts its review, with recommendations expected after their meeting. The company will provide updates following the DMC's formal recommendations, which may influence the trial's progression.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Notification regarding unquoted securities - RCE
- Amendments to Debt Facility with Avenue Capital Group
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - RCE
- Resolutions under section 249N of the Corporations Act
Later from Recce Pharmaceuticals
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - RCE
- Cleansing Notice
- Options Prospectus
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals